Key Data from the CYTO-PV and MAJIC-PV Studies: Evaluating Ruxolitinib in Polycythemia Vera

Dr. Pankit Vachhani presents key data from the CYTO-PV and MAJIC-PV studies, evaluating the efficacy of ruxolitinib versus best available therapy in patients with polycythemia vera, focusing on clinical outcomes such as cardiovascular risk reduction, hematocrit management, and long-term molecular responses.